Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis

204Citations
Citations of this article
270Readers
Mendeley users who have this article in their library.

Abstract

Neuromyelitis optica spectrum disorders (NMOSD) are autoantibody mediated chronic inflammatory diseases. Serum antibodies (Abs) against the aquaporin-4 water channel lead to recurrent attacks of optic neuritis, myelitis and/or brainstem syndromes. In some patients with symptoms of NMOSD, no AQP4-Abs but Abs against myelin-oligodendrocyte-glycoprotein (MOG) are detectable. These clinical syndromes are now frequently referred to as “MOG-encephalomyelitis” (MOG-EM). Here we give an overview on current recommendations concerning diagnosis of NMOSD and MOG-EM. These include antibody and further laboratory testing, MR imaging and optical coherence tomography. We discuss therapeutic options of acute attacks as well as longterm immunosuppressive treatment, including azathioprine, rituximab, and immunoglobulins.

Cite

CITATION STYLE

APA

Borisow, N., Mori, M., Kuwabara, S., Scheel, M., & Paul, F. (2018, October 23). Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Frontiers in Neurology. Frontiers Media S.A. https://doi.org/10.3389/fneur.2018.00888

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free